Rockwell Medical Reports Q4 Net Loss of $600,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy RMTI?
Source: moomoo
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.
Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMTI
Wall Street analysts forecast RMTI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.893
Low
2.50
Averages
3.75
High
5.00
Current: 0.893
Low
2.50
Averages
3.75
High
5.00
About RMTI
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rockwell Medical Q4 2025 Earnings Call Insights Highlight Operational Improvements and Growth Projections
- Customer Base Diversification: Rockwell Medical now serves approximately 300 customers in the U.S., including all five leading dialysis providers, with long-term agreements expected to drive sales growth in 2026, thereby strengthening its market position.
- Financial Performance Improvement: Q4 2025 net sales reached $18.3 million, a 15% increase from Q3, despite a 26% year-over-year decline, while gross margin improved from 14% in Q3 to 21%, indicating sustained profitability enhancements.
- Product Portfolio Expansion: The company introduced a single-use bicarbonate cartridge approved by the FDA 510(k), with expected sales of approximately $1 million in 2026, further enriching its product line and enhancing market competitiveness.
- Optimistic Future Outlook: Management projects adjusted EBITDA for 2026 to be between $1 million and $2 million, with positive cash flow expected to continue, and long-term goals include exceeding $100 million in annual sales by 2029, with gross margins approaching 30%.
See More
Rockwell Medical Reports Q4 Earnings Miss with Strategic Growth Plans for 2026
- Financial Overview: Rockwell Medical reported a Q4 Non-GAAP EPS of $0.02 with revenues of $18.3 million, reflecting a 25.8% year-over-year decline, which missed market expectations and indicates short-term financial challenges for the company.
- Cash Flow Position: Despite the revenue drop, the company generated $2.3 million in cash flow from operating activities in Q4, increasing its cash reserves to $25 million by year-end 2025, providing a buffer for future operations.
- Annual Performance Comparison: In 2025, Rockwell Medical achieved net sales of $69.3 million, aligning closely with its annual guidance of $65 million to $70 million but falling short of the market consensus of $75.15 million, highlighting intensified market competition.
- Future Growth Strategy: The company aims to drive sustainable, profitable growth in 2026 by adding new customers, renewing existing contracts, improving pricing and product mix, enhancing operational efficiencies, and selectively expanding its portfolio through disciplined partnerships, projecting Adjusted EBITDA between $1 million and $2 million.
See More
Rockwell Medical Reports Q4 Adjusted EPS of $0.02
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of kidney disease and related conditions.
Financial Performance: The company reported adjusted earnings per share (EPS) of $0.02 for the fourth quarter, indicating a positive financial outlook.
Product Development: Rockwell Medical continues to advance its product pipeline, aiming to enhance treatment options for patients with chronic kidney disease.
Market Position: The company is positioning itself strategically within the medical industry to address unmet needs in kidney care, potentially expanding its market share.
See More
Rockwell Medical Reports Q4 Net Loss of $600,000
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.
Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.
See More
Rockwell Medical Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Rockwell Medical (RMTI) is set to announce its Q4 2023 earnings on March 26 before the market opens, with a consensus EPS estimate of $0.02, reflecting a 50% year-over-year decline.
- Revenue Expectations Decline: Analysts forecast RMTI's Q4 revenue at $18.58 million, representing a 24.7% year-over-year decrease, indicating challenges and pressures the company faces in the current market environment.
- Historical Performance Review: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, demonstrating a degree of volatility in the company's financial performance.
- Increased Market Attention: As the earnings report approaches, investor interest in Rockwell Medical is rising, particularly in light of preliminary sales data exceeding expectations, which may influence market perceptions of its future performance.
See More
Rockwell Medical (RMTI) Reports 2025 Revenue Decline but Gross Margin Improvement
- Revenue Decline Expected: Rockwell Medical anticipates fourth-quarter net sales of approximately $18.6 million for 2025, down from $24.7 million in the prior year, indicating pressure in market competition.
- Full-Year Performance Drop: The expected full-year net sales for 2025 are around $69.5 million, lower than the $101.5 million reported last year, reflecting challenges in revenue growth for the company.
- Gross Margin Improvement: Despite the revenue decline, Rockwell Medical's gross margin for the fourth quarter increased to approximately 22% from 15% in the previous year, indicating progress in cost control and profitability.
- Future Strategic Focus: CEO Mark Strobeck stated that Rockwell will concentrate on revenue growth, increased profitability, and portfolio diversification in 2026, aiming to address current market challenges through these strategic initiatives.
See More
Rockwell Medical Q4 2025 Earnings Call Insights Highlight Operational Improvements and Growth Projections
- Customer Base Diversification: Rockwell Medical now serves approximately 300 customers in the U.S., including all five leading dialysis providers, with long-term agreements expected to drive sales growth in 2026, thereby strengthening its market position.
- Financial Performance Improvement: Q4 2025 net sales reached $18.3 million, a 15% increase from Q3, despite a 26% year-over-year decline, while gross margin improved from 14% in Q3 to 21%, indicating sustained profitability enhancements.
- Product Portfolio Expansion: The company introduced a single-use bicarbonate cartridge approved by the FDA 510(k), with expected sales of approximately $1 million in 2026, further enriching its product line and enhancing market competitiveness.
- Optimistic Future Outlook: Management projects adjusted EBITDA for 2026 to be between $1 million and $2 million, with positive cash flow expected to continue, and long-term goals include exceeding $100 million in annual sales by 2029, with gross margins approaching 30%.
See More
Rockwell Medical Reports Q4 Earnings Miss with Strategic Growth Plans for 2026
- Financial Overview: Rockwell Medical reported a Q4 Non-GAAP EPS of $0.02 with revenues of $18.3 million, reflecting a 25.8% year-over-year decline, which missed market expectations and indicates short-term financial challenges for the company.
- Cash Flow Position: Despite the revenue drop, the company generated $2.3 million in cash flow from operating activities in Q4, increasing its cash reserves to $25 million by year-end 2025, providing a buffer for future operations.
- Annual Performance Comparison: In 2025, Rockwell Medical achieved net sales of $69.3 million, aligning closely with its annual guidance of $65 million to $70 million but falling short of the market consensus of $75.15 million, highlighting intensified market competition.
- Future Growth Strategy: The company aims to drive sustainable, profitable growth in 2026 by adding new customers, renewing existing contracts, improving pricing and product mix, enhancing operational efficiencies, and selectively expanding its portfolio through disciplined partnerships, projecting Adjusted EBITDA between $1 million and $2 million.
See More
Rockwell Medical Reports Q4 Adjusted EPS of $0.02
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of kidney disease and related conditions.
Financial Performance: The company reported adjusted earnings per share (EPS) of $0.02 for the fourth quarter, indicating a positive financial outlook.
Product Development: Rockwell Medical continues to advance its product pipeline, aiming to enhance treatment options for patients with chronic kidney disease.
Market Position: The company is positioning itself strategically within the medical industry to address unmet needs in kidney care, potentially expanding its market share.
See More
Rockwell Medical Reports Q4 Net Loss of $600,000
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.
Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.
See More
Rockwell Medical Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Rockwell Medical (RMTI) is set to announce its Q4 2023 earnings on March 26 before the market opens, with a consensus EPS estimate of $0.02, reflecting a 50% year-over-year decline.
- Revenue Expectations Decline: Analysts forecast RMTI's Q4 revenue at $18.58 million, representing a 24.7% year-over-year decrease, indicating challenges and pressures the company faces in the current market environment.
- Historical Performance Review: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, demonstrating a degree of volatility in the company's financial performance.
- Increased Market Attention: As the earnings report approaches, investor interest in Rockwell Medical is rising, particularly in light of preliminary sales data exceeding expectations, which may influence market perceptions of its future performance.
See More
Rockwell Medical (RMTI) Reports 2025 Revenue Decline but Gross Margin Improvement
- Revenue Decline Expected: Rockwell Medical anticipates fourth-quarter net sales of approximately $18.6 million for 2025, down from $24.7 million in the prior year, indicating pressure in market competition.
- Full-Year Performance Drop: The expected full-year net sales for 2025 are around $69.5 million, lower than the $101.5 million reported last year, reflecting challenges in revenue growth for the company.
- Gross Margin Improvement: Despite the revenue decline, Rockwell Medical's gross margin for the fourth quarter increased to approximately 22% from 15% in the previous year, indicating progress in cost control and profitability.
- Future Strategic Focus: CEO Mark Strobeck stated that Rockwell will concentrate on revenue growth, increased profitability, and portfolio diversification in 2026, aiming to address current market challenges through these strategic initiatives.
See More
